Table 2.

Incidence rates (per 100 person-years [N of event per follow-up year]) for intensive and standard treatment groups, hazard ratios, and 95% confidence intervals for the effect of the intensive versus standard systolic BP intervention on serious adverse events in the Systolic Blood Pressure Intervention Trial participants with CKD by tertile of baseline diastolic BP

Adverse Event Type	Lowest tertile <69 mm Hg	Middle tertile =69–79 mm Hg	Highest tertile ≥80 mm Hg
Any serious adverse event a
Incidence rate
Intensive	24.3 (223/919)	21.6 (218/1010)	15.0 (187/1246)
Standard	26.4 (233/883)	18.5 (206/1111)	18.1 (202/1118)
HR (95% CI) intensive versus standard	0.93 (0.78 to 1.12)	1.11 (0.92 to 1.35)	0.84 (0.69 to 1.03)
Hypotension
Incidence rate
Intensive	1.0 (13/1263)	1.3 (18/1338)	1.1 (17/1525)
Standard	0.9 (11/1238)	0.8 (12/1423)	0.8 (11/1424)
HR (95% CI) intensive versus standard	1.14 (0.51 to 2.55)	1.55 (0.75 to 3.23)	1.37 (0.64 to 3.00)
Syncope
Incidence rate
Intensive	1.3 (16/1264)	1.1 (15/1349)	0.7 (10/1538)
Standard	0.9 (11/1244)	0.8 (12/1426)	0.5 (7/1431)
HR (95% CI) intensive versus standard	1.38 (0.64 to 3.00)	1.28 (0.60 to 2.74)	1.25 (0.46 to 3.37)
Electrolyte abnormality
Incidence rate
Intensive	1.8 (22/1245)	2.0 (27/1324)	0.9 (14/1532)
Standard	1.4 (17/1228)	0.8 (12/1425)	1.1 (16/1408)
HR (95% CI) intensive versus standard	1.37 (0.73 to 2.60)	2.33 (1.18 to 4.61)	0.73 (0.36 to 1.51)
AKI or acute kidney failure
Incidence rate
Intensive	3.7 (45/1220)	3.1 (41/1302)	1.8 (27/1515)
Standard	2.4 (29/1227)	1.6 (23/1418)	1.9 (27/1394)
HR (95% CI) intensive versus standard	1.53 (0.95 to 2.44)	1.81 (1.08 to 3.01)	1.00 (0.58 to 1.72)

HR, hazard ratio; 95% CI, 95% confidence interval.

^aModels adjusted for age, sex, race, cardiovascular disease, Framingham 10-year cardiovascular disease risk score ≥15%, smoking history, and baseline eGFR. Likelihood ratio tests comparing HRs for the systolic BP intervention among baseline diastolic BP tertiles were nonsignificant.